-
NMPA Re-elected as a Member of the ICH Management Committee
2025-02-19
On June 4, 2024, the plenary session of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was held in Fukuoka, Japan, at which the National Medical Products Administration (NMPA) was elected as a member of the ICH Management Committee for the third time.
-
Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug, Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) (trade name: 鼎优乐/XACDURO) of Entasis Therapeutics, Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Ivonescimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ivonescimab Injection (trade name: 依达方) of Akeso Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Rilertinib Mesylate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Rilertinib Mesylate Tablets (trade name: 圣瑞沙) of Nanjing Sanhome Pharmaceutical Limited Company is approved for marketing by China NMPA.
-
Envonalkib Citrate Capsules Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Envonalkib Citrate Capsules (trade name: 安洛晴) of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA.
-
Insulin icodec Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the insulin icodec injection (trade name: 诺和期/Awiqli) of Novo Nordisk A/S is approved for marketing by China NMPA.
